MXCT — MAXCYTE, INC.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1287098 ·
Last close
$1.17
Market Cap
$120.80M
52W High
$1.80
52W Low
$0.64
ADV30
1,690,855
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,152,000 | 8,468,000 | -6,041,000 | -4,762,000 | 182,483,000 | 13,372,000 | 31,552,000 |
| Jun 2026 | 7,271,000 | 5,596,000 | -10,232,000 | -8,874,000 | 184,672,000 | 15,042,000 | 25,920,000 |
| Mar 2026 | 9,651,000 | 8,082,000 | -6,185,000 | -4,750,000 | 194,473,000 | 14,557,000 | 26,587,000 |
| Dec 2025 | 7,300,000 | 5,690,000 | -7,672,000 | -9,596,000 | 202,507,000 | 20,065,000 | 31,017,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,025,000
Investing CF
$26,756,000
Financing CF
$-5,332,000
CapEx
$-574,000
Dividends Paid
—
Buybacks
$-4,022,000
EPS Diluted TTM
$-0.26
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-279,869,000
Inventory
$7,380,000
Receivables
$12,054,000
ST Investments
$87,908,000
EBIT TTM
$-30,130,000
Pretax Income TTM
$-27,982,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,051,000
EBITDA
$-30,288,000
Free Cash Flow
$-13,138,125
Enterprise Value
$45,729,068
Total Cash
$105,690,000
Total Debt
$17,251,000
Shares Out
103,250,292
Trailing EPS
$-0.26
Book Value
$1.61
ROE
-20.4%
ROA
-10.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 33,026,000 | -45,285,000 | -44,630,000 | 202,507,000 | 31,017,000 | 171,490,000 | -34,410,000 |
| Dec 2024 | 38,627,000 | -51,197,000 | -41,055,000 | 239,470,000 | 33,219,000 | 206,251,000 | -27,610,000 |
| Dec 2023 | 41,288,000 | -48,299,000 | -37,923,000 | 268,274,000 | 36,107,000 | 232,167,000 | -21,686,000 |
| Dec 2022 | 44,261,000 | -27,361,000 | -23,571,000 | 286,653,000 | 32,685,000 | 253,968,000 | -14,783,000 |
TTM Snapshot
Revenues TTM
$31,051,000
NetIncome TTM
$-35,636,000
OpCashFlow TTM
—
Assets (Latest)
$184,672,000
Forward EPS
$-0.23
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.25 · call volume: 20 · put volume: 50
Expected Move to 2027-04-16:
±$1.53
(122.00%) —
implied range
$-0.28 –
$2.78
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ICCC | IMMUCELL CORP /DE/ | $103.01M | $11.33 | — |
| NNNN | Anbio Biotechnology | $160.20M | $3.65 | — |
| IMDX | Insight Molecular Diagnostics Inc. | $58.25M | $1.78 | — |
| IBAC | IB Acquisition Corp. | $54.33M | $10.85 | — |
| ONMD | OneMedNet Corp | $293.47M | $4.95 | — |
News headlines (Yahoo Finance, 1h cache)
MaxCyte, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
2026-11-11 05:15 · Yahoo
MaxCyte Inc (MXCT) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% as Accron Acquisition ...
2026-11-11 05:09 · Yahoo
MaxCyte Q3 Earnings Call Highlights
2026-11-10 18:15 · Yahoo
MaxCyte to Acquire Akron Bio for $151.8 Million
2026-11-10 12:01 · Yahoo
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
2026-11-10 11:01 · Yahoo
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
2026-11-10 11:00 · Yahoo
MaxCyte to Participate in Three Upcoming Investor Conferences
2026-10-28 12:05 · Yahoo
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
2026-10-14 12:05 · Yahoo
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
2026-09-23 12:05 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-18 16:38:12 | 2026-11-17 | Masoud Maher | Pres, CEO | P - Purchase | 1.21 | 100000 | 120780 |